MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2016 International Congress

    Mitochondrial dysfunction in skin fibroblasts from single heterozygous ATP13A2 (PARK9) mutation carriers

    J.S. Park, C. Klein, C.M. Sue (St. Leonards, Australia)

    Objective: To investigate the pathogenic effect of single heterozygous mutations in ATP13A2, we determined the function and morphological changes of mitochondria in skin fibroblasts derived…
  • 2016 International Congress

    Defective ubiquitinated mitochondria accumulation in aged Parkinsonian LRRK2R1441G knockin mice

    H.F. Liu, P.W.L. Ho, L.F. Li, G.C.T. Leung, C.S.C. Lam, M.H.W. Kung, D.B. Ramsden, S.L. Ho (Hong Kong, Hong Kong)

    Objective: (1) To determine potential accumulation of defective ubiquitinated mitochondria in the brains of aged LRRK2R1441G knockin (KI) mice and their age-matched wildtype controls; and…
  • 2016 International Congress

    The correlation between N30 SEP and motor function in Parkinson’s disease

    S.Y. Kang, Y.J. Kim, Y.H. Sohn, H.I. Ma (Hwaseong, Korea)

    Objective: To investigate frontal N30 in Parkinson's disease (PD), and to examine the correlation between amplitude of frontal N30 and the degree of motor deficits.…
  • 2016 International Congress

    Vascular degeneration in Parkinson’s disease

    J. Guan, P. Yang, R.L.M. Faill, M. Dragunow, H.J. Waldvogel (Auckland, New Zealand)

    Objective: To determine the role vascular degeneration in human Parkinson's disease (PD). Background: We have previously reported endothelial degeneration in the PD. Current study examined…
  • 2016 International Congress

    Increased anti-MAG autoantibodies titers in Parkinson’s disease

    E. Papuc, K. Rejdak (Lublin, Poland)

    Objective: To search for biomarkers of neurodegenerative process in Parkinson's disease (PD).There is emerging evidence that humoral response may be involved in the pathogenesis and…
  • 2016 International Congress

    Toward a new biomarker on Parkinson’s disease: Study of alpha synuclein on upper enteric system by endoscopy

    N. Ben Ali, S. Mrabet, S. Hawet, R. Debbiche, S. Belal (Tunis, Tunisia)

    Objective: The aim of our study was to investigate the alpha synuclein deposition at the enteric nerve system on patient with Parkinson's disease and provide…
  • 2016 International Congress

    Alpha-synuclein in gastric and colonic mucosa in Parkinson’s disease: Limited role as a biomarker

    S.J. Chung, J. Kim, H.J. Lee, H.S. Ryu, K.W. Jung, M.J. Kim, M.J. Kim, S.M. Hong, S.J. Myung (Seoul, Korea)

    Objective: We aimed to investigate the utility of alpha-synuclein (α-SYN) immunoreactivity from gastric and colonic mucosal tissues obtained by routine endoscopy to detect Parkinson's disease…
  • 2016 International Congress

    Longitudinal measurements of cerebrospinal fluid biomarkers in Parkinson’s disease

    S. Hall, Y. Surova, A. Öhrfelt, K. Blennow, H. Zetterberg, O. Hansson (Lund, Sweden)

    Objective: To investigate whether cerebrospinal fluid (CSF) levels of tau, phosphorylated tau, β-amyloid42, α-synuclein, neurofilament light and YKL-40 change over time and if changes correlate…
  • 2016 International Congress

    Objective methods for quantifying the deep brain stimulation (DBS) efficacy in subthalamic-nuclei (STN) neurons with microelectrode recording (MER) technology

    V.R. Rama Raju, R.K. Mridula, R. Borgohain, V. Rama Raju (Hyderabad, India)

    Objective: To design a computational modeling to develop a new diagnostic tool for effective neuro-medical-diagnostics for end users, to investigate and evaluate the potential benefits…
  • 2016 International Congress

    Counteracting PINK1/parkin deficiency by activating alternative mitophagic pathway: a potential therapeutic intervention for Parkinson’s disease

    B. Koentjoro, J.S. Park, C.M. Sue (Sydney, Australia)

    Objective: To identify a new therapeutic target for developing neuroprotective treatment in Parkinson's disease (PD) by improving mitochondrial function through restoration of mitochondrial quality control…
  • « Previous Page
  • 1
  • …
  • 1596
  • 1597
  • 1598
  • 1599
  • 1600
  • …
  • 1734
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley